Additional immunotherapy on the basis of increasing mixed hematopoietic chimerism after allogeneic BMT in children with acute leukemia: is there an option to prevent relapse?
The success of allogeneic BMT (allo-BMT) in children with acute leukemias is mainly affected by relapse. There is evidence that these patients have only a little or no benefit from additional immunotherapy if the treatment is started in frank hematological relapse. Recently we were able to demonstrate that pediatric patients with acute leukemias and increasing mixed chimerism (MC) post-transplant have a significantly enhanced risk of developing relapse. We asked whether there is a possibility of preventing relapse, eg by withdrawal of post-transplant immunosuppression or by administration of donor lymphocytes in an early phase of the development of relapse. We present the case reports of two children (MDS and AML) with rapidly increasing MC in whom withdrawal of post-transplant immunosuppression or donor lymphocyte infusion (DLI) did prevent relapse.
Bader
P
P
University Children's Hospital, Department of Hematology/Oncology, Tuebingen, Germany.
Beck
J
J
Schlegel
P G
PG
Handgretinger
R
R
Niethammer
D
D
Klingebiel
T
T
D000208:Acute Disease; D016026:Bone Marrow Transplantation; D002675:Child, Preschool; D006801:Humans; D007167:Immunotherapy; D007938:Leukemia / Q000628:therapy*; D008297:Male; D012008:Recurrence; D018183:Transplantation Chimera / Q000276:immunology*; D014184:Transplantation, Homologous